Follicular Lymphoma
Conditions
Brief summary
The study is being conducted to evaluate the efficacy and safety of SHR2554 in Patients with Relapsed or Refractory Follicular Lymphoma
Interventions
DRUGSHR2554
SHR2554
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Males or females aged ≥18 years 2. Histologically confirmed follicular lymphoma 3. Eastern Cooperative Oncology Group performance status (ECOG PS) score ≤2 4. Life expectancy ≥ 12 weeks 5. Treated with CD20 antibody, refractory to or relapse from prior anti-cancer therapies 6. Have measurable lesions 7. The subject is willing and able to comply with the visit schedule, dosing schedule, laboratory tests, and other clinical study procedures
Exclusion criteria
1. Have been treated with a compound of the same machanism; 2. Accompanied by central nervous system infiltration; 3. Received autologous stem cell transplantation within 60 days before signing the agreement, and received allogeneic stem cell transplantation or CAR-T therapy within 90 days; 4. Underwent major surgery or experienced severe trauma within 4 weeks prior to the first dose of the investigational drug 5. Known active infection 6. History of clinically severe cardiovascular diseases 7. Have other malignancies within 5 years prior to screening Pregnant or lactating women 8. The subject is unable to swallow, or has a history of active gastrointestinal inflammation, chronic diarrhea, known diverticulosis, or a history of gastrectomy or gastric banding that affects drug absorption. 9. The subject is taking a known medium or strong CYP inducer. 10. Based on the investigator's judgment, there are objective conditions that may prevent the subject from completing the study as planned or the subject has other factors, concomitant diseases, concomitant treatments, or abnormal laboratory findings that may lead to early study termination
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate (ORR) assessed by independent review committee (IRC) | around 1 year | percentage of patients who achieve completes response(CR) or partial response(PR) in the study |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ORR assessed by investigator | around 1 year | percentage of patients who achieve CR or PR in the study |
| Progression free survival | around 1 year | time from the first dose of SHR2554 to the first disease progression(PD) or death |
| Time to Response | around 4 months | time from the first dose of SHR2554 to first CR or PR |
| Duration of response | around 1 year | time from the first CR or PR to the first PD or death |
| Overall survival | around 5 years | time from the fist dose of SHR2554 to death |
Countries
China
Contacts
Primary ContactZhenyu Xiao
Outcome results
None listed